Empagliflozin in paroxysmal or persistent atrial fibrillation: a possible antiarrhythmic effect
Abstract
Background: Many studies have highlighted an increased risk of developing atrial fibrillation (AF) in diabetic patients. The SGLT2 inhibitors, in addition to glycaemic control, have shown pleiotropic effects on the cardiovascular system, proving to be particularly advantageous in patients with heart failure. In this study we evaluated a group of patients with paroxysmal AF (PAF) or persistent AF (PeAF) affected by type 2 diabetes and treated with empagliflozin. Methods: This is a case-crossover study obtained from our database of patients affected by PAF or PeAF. We extracted 23 consecutive subjects ICD wearers and affected by diabetes that started treatment with empagliflozin during the follow-up. Results: All enrolled patients were ICD wearers because at high risk of sudden cardiac death and received amiodarone; empagliflozin was added during follow-up for the treatment of diabetes. We evaluated the recurrence of PAF and the days free from AF one year before and one year after starting treatment with empagliflozin. The recurrence of AF was significantly lower after starting empagliflozin than before the treatment (p: 0.001). Conclusion: Our data suggest that empagliflozin is able to reduce the recurrences of AF in diabetic patients with PAF or PeAF. Further studies might demonstrate an antiarrhythmic effect of empagliflozin and change the therapeutic approach in subjects at high risk of AF.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.